Karyopharm Therapeutics Receives a Buy from Cantor Fitzgerald

By Austin Angelo

In a report released today, Mara Goldstein from Cantor Fitzgerald reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $18. The company’s shares opened today at $9.64.

Goldstein observed:

“Support for KPTI’s DLBCL program (SADAL) could build with a presentation at the EHA (Abstract S469) in June.”

According to TipRanks.com, Goldstein is ranked 0 out of 5 stars with an average return of -2.4% and a 40.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Cascadian Therapeutics.

Currently, the analyst consensus on Karyopharm Therapeutics is Strong Buy and the average price target is $18, representing an 86.7% upside.

In a report issued on May 4, Canaccord Genuity also reiterated a Buy rating on the stock with a $17 price target.

Based on Karyopharm Therapeutics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $68K and GAAP net loss of $29.92 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $27.06 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, which discovers, develops, and commercializes drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.